Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 15, 2026 | September 15, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | February 02, 2024 | February 06, 2024 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,184 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,000 · Balance 8,184 |
REGENERON PHARMACEUTICALS, INC.
Report date February 02, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,693 |
Ending reported balance
After 2024-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-02 · Exercise / conversion · Acquired 400 · Balance 23,974 Row 2 · 2024-02-02 · Tax withholding · Disposed 281 · Balance 23,693 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12 | Direct | 11,787 |
Reported balance
After 2024-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-02 · Exercise / conversion · Disposed 400 · Balance 11,787 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 270 |
Reported balance
Holding disclosure · report date 2024-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 270 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $455.13 | $7,737.21 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 14 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,173 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $454.67 | $1,818.68 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 13 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,190 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $453.60 | $7,257.60 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,194 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 35 | $450.80 | $15,778.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,210 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 35 shares of Company stock on February 25, 2020 at prices ranging from $450.70 to $450.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 54 | $449.50 | $24,273.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 54 shares of Company stock on February 25, 2020 at prices ranging from $449.01 to $449.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $448.54 | $8,073.72 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,299 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 37 | $447.11 | $16,543.07 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,317 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 37 shares of Company stock on February 25, 2020 at prices ranging from $447.00 to $447.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $445.35 | $4,898.85 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,354 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $444.03 | $5,328.36 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,365 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $438.00 | $4,380.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,377 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 800 | $447.30 | $357,840.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,387 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $272.70 | $272,700.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · derivative · entry 24 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,500 Underlying: Common Stock · 1,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 786 | $406.59 | $319,579.74 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,187 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 23:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $272.70 | $272,700.00 |
DisclosureSEC source: 0001708138-20-000012 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $407.66 | $2,038.30 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,973 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $402.30 | $1,609.20 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,978 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $401.70 | $3,213.60 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,982 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21 | $400.54 | $8,411.34 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,990 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 21 shares of Company stock on February 13, 2020 at prices ranging from $400.20 to $400.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22 | $399.89 | $8,797.58 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,011 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 22 shares of Company stock on February 13, 2020 at prices ranging from $399.78 to $399.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 47 | $398.63 | $18,735.61 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,033 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 47 shares of Company stock on February 13, 2020 at prices ranging from $398.62 to $398.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · derivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 393 | $402.34 | $158,119.62 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,080 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $272.70 | $136,350.00 |
DisclosureSEC source: 0001237899-20-000009 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,500 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000033 · edgardoc.xml · derivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-12-11 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000033 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,973 F2 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 11, 2023. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000033 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,973 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001237899-18-000019 · edgardoc.xml · derivative · entry 3 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-12-12 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000019 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,348 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 12, 2023. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,251 | $395.29 | $889,797.79 |
DisclosureSEC source: 0001708138-18-000021 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,848 Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 23,337 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000025 · edgardoc.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,337 Underlying: Common Stock · 23,337 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $499.69 | $49,969.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,099 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $498.25 | $49,825.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,199 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $496.86 | $49,686.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,299 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 74 | $496.52 | $36,742.48 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,399 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $496.51 | $49,651.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,473 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 89 | $501.88 | $44,667.32 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,573 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $500.33 | $50,033.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,662 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · derivative · entry 12 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 3,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 706 | $501.29 | $353,910.74 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,762 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,631 | $501.29 | $817,603.99 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,468 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $272.70 | $818,100.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 127 | $497.69 | $63,206.63 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,099 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $497.42 | $49,742.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $489.56 | $48,956.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,326 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $487.88 | $48,788.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,426 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · derivative · entry 9 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 2,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 454 | $486.91 | $221,057.14 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,526 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,119 | $486.91 | $544,852.29 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,980 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $272.70 | $545,400.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.